Health Care · Pharmaceutical Preparations · NYSE · CIK 1131399 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $53.71Day +3.33%1Y +43.4%Off 52W high −12.9%Vol (1Y) 27.3%
Daily closing price, split-adjusted to the current basis; 2.9y shown of 4,015 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.3% of sh out |
| Days to cover4.5d |
| 13F net flow (QoQ)−0.48% |
| Top-10 13F concentration65.9% |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)£32.67B |
| Earnings (TTM)£5.72B |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (GBP). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+9.5% |
| 1Y+43.4% |
| 3Y+51.6% |
| 5Y+36.0% |
| 10Y+18.9% |
| Since incept. (ann.)+1.5% |
Price return through 2026-07-28 · series begins 2010-01-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)27.3% |
| Ann. volatility (3Y)25.0% |
| Sharpe (1Y)1.52 |
| Sharpe (3Y)0.67 |
| Max drawdown (1Y)−18.8% |
| Max drawdown (3Y)−29.9% |
| Beta (3Y vs SPY)−0.07 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 67.7M | $3.7B | 1.57% | +0.3% |
| Dodge & Cox | 58.7M | $3.2B | 1.36% | −14.4% |
| Fisher Asset Management, LLC | 34.5M | $1.9B | 0.80% | +4.0% |
| PRIMECAP MANAGEMENT CO/CA/ | 25.2M | $1.4B | 0.58% | +0.3% |
| ACADIAN ASSET MANAGEMENT LLC | 11.8M | $651M | 0.27% | +31.6% |
| WELLINGTON MANAGEMENT GROUP LLP | 11.7M | $647M | 0.27% | −6.7% |
| MORGAN STANLEY | 11.0M | $609M | 0.26% | +89.2% |
| GOLDMAN SACHS GROUP INC | 9.6M | $529M | 0.22% | +32.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
No reported quarters on file for GSK.
